• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Abbott’s latest drug-eluting stent

May 23, 2018 By Sarah Faulkner

AbbottAbbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent.

The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott.

“We developed XIENCE Sierra so that physicians can more easily deliver the stent even in challenging cases,” Chuck Brynelsen, SVP of Abbott’s vascular unit, said in prepared remarks. “The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”

Abbott won CE Mark clearance for Xience Sierra in October last year and regulatory approval in Japan earlier this year. The device has been used in more than 8 million people worldwide, Abbott touted.

Last year, the company touted results from a quality-of-life analysis based on data from its Xience Excel study, which enrolled 1,905 people to compare the safety and efficacy of percutaneous coronary intervention with Abbott’s Xience coronary stent and coronary artery bypass grafting in patients with left main coronary artery disease.

After one month, one year and three years, patients were asked to report the frequency of things like angina and symptoms of depression.

Patients who were treated with Xience reported significantly greater freedom from angina and 60% of them said they had no difficulty breathing compared to 44% of people who had surgery.

Also last year, reports surfaced revealing that Abbott will not introduce its Xience Sierra stent to the Indian market due to measures that cap the prices for metal, drug-eluting and bioresorbable stents.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS